BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25179825)

  • 1. Drug metabolism in microorganisms.
    Murphy CD
    Biotechnol Lett; 2015 Jan; 37(1):19-28. PubMed ID: 25179825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric cytochromes P450 engineered by domain swapping and random mutagenesis for producing human metabolites of drugs.
    Kang JY; Ryu SH; Park SH; Cha GS; Kim DH; Kim KH; Hong AW; Ahn T; Pan JG; Joung YH; Kang HS; Yun CH
    Biotechnol Bioeng; 2014 Jul; 111(7):1313-22. PubMed ID: 24474032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human cytochrome P450 monooxygenases for drug metabolite synthesis.
    Schroer K; Kittelmann M; Lütz S
    Biotechnol Bioeng; 2010 Aug; 106(5):699-706. PubMed ID: 20506361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cunninghamella--a microbial model for drug metabolism studies--a review.
    Asha S; Vidyavathi M
    Biotechnol Adv; 2009; 27(1):16-29. PubMed ID: 18775773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
    Yun CH; Kim KH; Kim DH; Jung HC; Pan JG
    Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
    Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
    Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotransformation of fluorinated drugs and xenobiotics by the model fungus Cunninghamella elegans.
    Khan MF; Hof C; Niemcova P; Murphy CD
    Methods Enzymol; 2024; 696():251-285. PubMed ID: 38658083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of cytochrome P450 mediated metabolism.
    Olsen L; Oostenbrink C; Jørgensen FS
    Adv Drug Deliv Rev; 2015 Jun; 86():61-71. PubMed ID: 25958010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-cytochrome P450-mediated bioactivation and its toxicological relevance.
    Gan J; Ma S; Zhang D
    Drug Metab Rev; 2016 Nov; 48(4):473-501. PubMed ID: 27533622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450-mediated metabolism in the human gut wall.
    Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro tool to assess cytochrome P450 drug biotransformation-dependent cytotoxicity in engineered HepG2 cells generated by using adenoviral vectors.
    Lahoz A; Vilà MR; Fabre M; Miquel JM; Rivas M; Maines J; Castell JV; Gómez-Lechón MJ
    Toxicol In Vitro; 2013 Jun; 27(4):1410-5. PubMed ID: 22910125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
    Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
    Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of density functional theory in drug metabolism studies.
    Rydberg P; Jørgensen FS; Olsen L
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):215-27. PubMed ID: 24295134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regioselective hydroxylation of 17β-estradiol by mutants of CYP102A1 from Bacillus megaterium.
    Cha GS; Ryu SH; Ahn T; Yun CH
    Biotechnol Lett; 2014 Dec; 36(12):2501-6. PubMed ID: 25129047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cunninghamella Biotransformation--Similarities to Human Drug Metabolism and Its Relevance for the Drug Discovery Process.
    Piska K; Żelaszczyk D; Jamrozik M; Kubowicz-Kwaśny P; Pękala E
    Curr Drug Metab; 2016; 17(2):107-17. PubMed ID: 26526834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450s in the development of target-based anticancer drugs.
    Purnapatre K; Khattar SK; Saini KS
    Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics.
    Martinez MN; Antonovic L; Court M; Dacasto M; Fink-Gremmels J; Kukanich B; Locuson C; Mealey K; Myers MJ; Trepanier L
    Drug Metab Rev; 2013 May; 45(2):218-30. PubMed ID: 23432217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Streptomyces cytochromes P450: applications in drug metabolism.
    Lamb DC; Waterman MR; Zhao B
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1279-94. PubMed ID: 23738914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli.
    McGinnity DF; Griffin SJ; Moody GC; Voice M; Hanlon S; Friedberg T; Riley RJ
    Drug Metab Dispos; 1999 Sep; 27(9):1017-23. PubMed ID: 10460801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.